D. J. Selkoe, Alzheimer's disease: genes, proteins and therapy, Physiol. Rev, vol.81, p.11274343, 2001.

J. A. Hardy and G. A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis, Science, vol.256, p.1566067, 1992.

K. Blennow, M. J. De-leon, and H. Zetterberg, Alzheimers disease, Lancet, vol.368, pp.387-403, 2006.
URL : https://hal.archives-ouvertes.fr/hal-01098836

D. Selkoe and D. Schenk,

, Alzheimer's disease: molecular understanding predictsamyloid-based therapeutics, Annu. Rev. Pharmacol. Toxicol, vol.43, p.12415125, 2003.

M. D. Greicius, G. Srivastava, A. L. Reiss, and V. Menon, Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI, Proc. Natl. Acad. Sci. U. S. A, vol.101, issue.13, p.15070770, 2004.

J. T. Coyle, D. L. Price, and M. R. Delong, Alzheimer's disease: a disorder of cortical cholinergic innervation, Science, vol.219, p.6338589, 1983.

M. R. Hynd, H. L. Scott, and P. R. Dodd, Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease, Neurochem. Int, vol.45, issue.5, p.15234100, 2004.

R. S. Shah, H. G. Lee, Z. Xiongwei, G. Perry, M. A. Smith et al., Current approaches in the treatment of Alzheimer's disease, Biomed. Pharmacother, vol.62, issue.4, p.18407457, 2008.

P. Davies and A. J. Maloney, Selective loss of central cholinergic neurons in Alzheimer's disease, Lancet, vol.2, issue.8000, p.1403, 1976.

K. L. Lanctot, N. Herrmann, K. K. Yau, L. R. Khan, B. A. Liu et al., Efiicacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis, C.M.A.J, vol.169, issue.6, pp.557-564, 2003.

G. M. Shankar, D. L. Bloodgood, M. Townsend, D. M. Walsh, D. J. Selkoe et al., Natural oligomers of the Alzheimer amyloid-beta induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependant signalling pathway, J. Neurosci, vol.27, pp.2866-2875, 2007.

/. Jneurosci, , p.17360908, 2007.

P. N. Lacor, M. C. Buniel, P. W. Furlow, A. S. Clemente, P. T. Velasco et al., A beta-oligomer induced abberation in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease, J. Neurosci, vol.27, pp.796-807, 2007.

/. Jneurosci, , p.17251419, 2007.

S. Lesne, M. T. Koh, L. Kotilinek, R. Kayed, R. Kayed et al., A specific amyloid-beta protein assembly in the brain impairs memory, Nature, vol.440, p.16541076, 2006.

P. Davies and B. L. Wolozin, Recent advances in the neurochemistry of Alzheimer's disease, J. Clin. Psychiatry, vol.48, p.2883177, 1987.

R. Strong, Neurochemical changes in the aging human brain: implications for behavioural impairment and neurodegenerative disease, Geriatrics, vol.53, p.9745628, 1998.

D. S. Auld, T. J. Kornecook, S. Bastianetto, and R. Quirion, Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies, Prog. Neurobiol, vol.68, issue.3, p.12450488, 2002.

D. Prvulovic and B. Schneider, Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease, Expert Opin. Drug Metab. Toxicol, vol.10, p.24785550, 2014.

J. Birks and R. J. Harvey, Donepezil for dementia due to Alzheimer's disease, Cochrane Database Syst. Rev, p.16437430, 2006.

Q. Li, M. Chen, H. Liu, L. Yang, and G. Yang, Expression of APP, BACE1, AChE and ChAT in an AD model in rats and the effect of donepezil hydrochloride treatment, Mol. Med. Rep, vol.6, issue.6, p.23023803, 2012.

H. Ogura, T. Kosasa, Y. Kuriya, and Y. Yamanishi, Donepezil, a centrally acting acetyl ChE inhibitor, alleviates learning deficits in hypocholinergic models in rats, Methods Find. Exp. Clin. Pharmacol, vol.22, p.10849891, 2000.

A. Kurz and T. Grimmer, Efficacy of memantine hydrochloride once-daily in Alzheimer's disease, Expert Opin. Pharmacother, vol.15, issue.13, p.25085661, 2014.

R. Mcshane, A. Sastre, A. Minakaran, and N. , Memantine for dementia, Cochrane Database Syst. Rev, vol.003154, p.16625572, 2006.

S. Bakchine and H. Loft, Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6 month study, J. Alzheimers Dis, vol.11, p.17656827, 2007.

R. Minkeviciene, P. Banerjee, and H. Tanila, Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease, J. Pharmacol. Exp. Ther, vol.311, p.15192085, 2004.

M. Vercelletto, C. Boutoleau-bretonnière, C. Volteau, M. Puel, S. Auriacombe et al., Lacomblez L; French research network on Frontotemporal dementia. Memantine in behavioural variant fronto temporal dementia, J. Alzheimers Dis, vol.23, issue.4, p.21157021, 2011.

C. Creeley, D. F. Wozniak, J. Labruyere, G. T. Taylor, and J. W. Olney, Low doses of memantine disrupt memory in adult rats, J. Neurosci, vol.26, p.16611808, 2006.

D. Repantis, O. Laisney, and I. Heuser, Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systemic review, Pharmacol. Res, vol.61, p.20193764, 2010.

D. S. Geldmacher, Long-term cholinesterase inhibitor therapy for Alzheimer's disease: practical considerations for the primary care physician, Prim. Care Companion J. Clin. Psychiatry, vol.5, issue.6, p.15213795, 2003.

A. Burns, M. Rossor, J. Hecker, S. Gauthier, H. Petit et al., The effects of donepezil in Alzheimer's disease results from a multinational trial, Dement. Geriatr. Cogn. Disord, vol.10, issue.3, p.10325453, 1999.

S. Gauthier, H. Loft, and J. Cummings, Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis, Int. J. Geriatr. Psychiatry, vol.23, issue.5, p.18058838, 2008.

P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan et al., Effectiveness of cholinesterase inhibitors and mematine for treating dementia: evidence review for a clinical practice guideline, Ann. Intern. Med, vol.148, issue.5, p.18316756, 2008.

M. Windisch, We can treat Alzheimer's disease successfully in mice but not in men: failure in translation? A perspective, Neurodegener. Dis, vol.13, issue.2-3, p.24401335, 2014.

B. Laurijssens, F. Aujard, and A. Rahman, Animal model of Alzheimer's disease and drug development, Drug Discov. Today Technol, vol.10, issue.3, p.24050129, 2013.

S. Languille, S. Blanc, O. Blin, C. I. Canale, A. Dal-pan et al., The grey mouse lemur: a non-human primate model for ageing studies, Ageing Res. Rev, vol.11, issue.1, p.21802530, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00650159

J. L. Picq, F. Aujard, A. Volk, and M. Dhenain, Age-related cerebral atrophy in non-human primates predicts cognitive impairments, Neurobiol. Aging, vol.33, issue.6, p.20970891, 2012.

, Donepezil or memantine limit sleep-deprivation-induced memory deficit in young and aged non-human primate, PLOS ONE, 2017.

F. D. Weatherall, The use of non-human primate in research, The Weatherall report, 2006.

F. Pifferi, A. Rahman, S. Languille, A. Auffret, C. Babiloni et al., Effects of dietary resveratrol on the sleep-wake cycle in the non-human primate grey mouse lemur (Microcebus murinus), Chronobiol. Int, vol.29, issue.3, p.22390239, 2012.

I. H. Gomolin, C. Smith, and T. M. Jeitner, Once-daily memantine: pharmacokinetic and clinical considerations, J. Am. Geriatr. Soc, vol.58, issue.9, p.20863351, 2010.

A. Periclou, D. Ventura, N. Rao, and W. Abramowitz, Pharmacokinetic study of memantine in healthy and renally impaired subjects, Clin. Pharmacol. Ther, vol.79, issue.1, p.16413248, 2006.

S. Umukoro, F. A. Adewole, A. T. Eduviere, A. O. Aderibigbe, and C. Onwuchekwa, Free radical scavenging effect of donepezil as the possible contribution to its memory enhancing activity in mice, Drug Res. (Stuttg), vol.64, issue.5, pp.236-239, 2014.

Z. Xia, R. Zhang, P. Wu, Z. Xia, and Y. Hu, Memory defect induced by ß-amyloid plus glutamate receptor agonist is alleviated by catalpol and donepezil through different mechanisms, Brain Res, vol.1441, p.22305339, 2012.

H. Martinez-coria, K. N. Green, L. M. Billings, M. Kitazawa, M. Albrecht et al., Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice, Am. J. Pathol, vol.176, pp.870-880, 2010.

H. Scholtzova, Y. Z. Wadghiri, M. Douadi, E. M. Sigurdsson, Y. S. Li et al., Wisniewski T. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-diseasemodel transgenic mice shown as by micromagnetic resonance imaging, J. Neurosci. Res, pp.224-57, 2008.

A. Nagakura, Y. Shitaka, J. Yarimizu, and N. Matsuoka, Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine, Eur. J. Pharmacol, vol.703, issue.1-3, p.23276665, 2013.

J. Ihalainen, T. Sarajarvi, D. Rasmusson, S. Kemppainen, P. Keski-rahkonen et al., Effects of memantine and donepezil on cortical and hippocampal acetylcholine levels and object recognition memory in rats, Neuropharmacology, vol.61, issue.5-6, p.21704049, 2011.

I. Tobler and A. A. Borbély, The effect of 3-h and 6-h sleep deprivation on sleep and EEG spectra of the rat, Behav. Brain Res, vol.36, issue.1-2, p.2302323, 1990.

R. Hagewoud, R. Havekes, P. A. Tiba, A. Novati, K. Hogenelst et al., Coping with sleep deprivation: shifts in regional brain activity and learning strategy, Sleep, vol.33, issue.11, p.21102988, 2010.

R. A. Lenz, J. D. Baker, C. Locke, L. E. Rueter, E. G. Mohler et al., The scopolamine model as a pharmacodynamic marker in early drug development, Psychopharmacology (Berl), vol.220, issue.1, pp.97-107, 2012.

G. R. Dawson and S. D. Iverson, The effects of novel ChE inhibitors and selective muscarinic receptor agonists in test of reference and working memory, Behav. Brain Res, vol.57, p.8117420, 1993.

Z. Chen, A. J. Xu, R. Li, and E. Q. Wei, Reversal of scopolamine induced spatial memory deficits in rats by TAK-147, Acta Pharmacol. Sin, vol.23, issue.4, p.11931694, 2002.

A. Easton, S. Sankaranarayanan, A. Tanghe, D. Terwel, A. X. Lin et al., Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease, Psychopharmacology (Berl), vol.230, issue.2, pp.279-289, 2013.

L. Y. Chuah and M. W. Chee, Cholinergic augmentation modulates visual task performance in sleep-deprived young adults, J. Neurosci, vol.28, issue.44, p.18971479, 2008.

L. Y. Chuah, D. L. Chong, A. K. Chen, W. Rekshan, J. C. Tan et al., Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation, Sleep, vol.32, issue.8, p.19725251, 2009.

D. Braida, E. Paladini, P. Griffini, M. Lamperti, A. Maggi et al., An inverted U-shaped curve for hepatylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors, Eur. J. Pharmacol, vol.302, issue.1-3, p.8790986, 1996.

J. F. Flood, D. W. Landry, and M. E. Jarvik, Cholinergic receptor interactions and their effects on long-term memory processing, Brain Res, vol.215, issue.1-2, p.7260586, 1981.

R. L. Michaels and S. M. Rothman, Glutamate neurotoxicity in vitro: antagonist pharmacology and intracellular calcium concentrations, J. Neurosci, vol.10, p.1967639, 1990.

P. T. Francis, M. T. Webster, I. P. Chessell, C. Holmes, G. C. Stratmann et al., Neurotransmitters and second messengers in aging and Alzheimer's disease, Ann. NY. Acad. Sci, vol.695, p.7902054, 1993.

J. T. Greenamyre and A. B. Young, Excitatory amino acids and Alzheimer's disease, Neurobiol. Aging, vol.10, p.2554168, 1989.

D. Van-dam and P. P. De-deyn, Cognitive evaluation of disease modifying efficacy of galantamine and memantine in APP23 model, Eur. Neuropsychopharmacol, vol.16, issue.1, p.16095884, 2006.

E. Tarragon, D. Lopez, C. Estrada, A. Gonzalez-cuello, C. M. Ros et al., Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus, Neuropharmacology, vol.85, p.24878242, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02309703

M. M. Schugens, R. Egerter, I. Daum, K. Schepelmann, T. Klockgether et al., The NMDA antagonist memantine impairs classical eyeblink conditioning in humans, Neurosci. Lett, vol.224, p.9132691, 1997.

T. H. Rammsayer, Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans, Neurobiol. Learn. Mem, vol.8, pp.20-25, 2001.

M. Korostenskaja, V. V. Nikulin, D. Kicic, A. V. Nikulina, and S. Kahkonen, Effects of NMDA receptor antagonist memantine on mismatch negativity, Brain Res. Bull, vol.72, p.17452287, 2007.

P. N. Tariot, M. R. Farlow, G. T. Grossberg, S. M. Graham, S. Mc-donald et al., Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial, JAMA, vol.291, p.14734594, 2004.

B. Reisberg, R. Doody, A. Stoffler, F. Schmitt, S. Ferris et al., A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease, Arch. Neurol, vol.63, p.16401736, 2006.

N. Bons, F. Rieger, D. Prudhomme, A. Fisher, and K. H. Krause, Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease?, Genes Brain Behav, vol.5, issue.2, p.16507003, 2006.

S. Languille, A. Liévin-bazin, J. L. Picq, C. Louis, S. Dix et al., Deficits of psychomotor and mnesic functions across aging in mouse lemur primates, Front Behav Neurosci, vol.9, p.25620921, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01230922

J. S. Schneider, E. Y. Pioli, Y. Jianzhong, Q. Li, and E. Bezard, Effects of memantine and galantamine on cognitive performance in aged rhesus macaques, Neurobiol Aging, vol.34, p.23158762, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01218078